Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Goldstein

Showing results (1-10 of 136) with videos related to

Pageof 14
Sort By:
JAMA Oncology|June 1, 2016
The Ethical and Practical Challenges of Value-Based Cancer Care at the Patient's BedsideDaniel A Goldstein
JAMA Oncology|October 7, 2017
Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient RegimenDaniel A Goldstein
Haematologica|May 2, 2018
Denosumab for bone lesions in multiple myeloma - what is its value?Daniel A Goldstein
Cancer|February 21, 2017
Financial toxicity in cancer care-Edging toward solutionsDaniel A Goldstein
Journal of Oncology Practice|May 5, 2016
Using Quality-Adjusted Life-Years in Cost-Effectiveness Analyses: Do Not Throw Out the Baby or the BathwaterDaniel A Goldstein
Cancer|May 11, 2016
Understanding the value of cancer drugs-the devil is in the detailDaniel A Goldstein
Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology|May 7, 2014
Tempest in a tea pot: How did the public conversation on genetically modified crops drift so far from the facts?Daniel A Goldstein
Mayo Clinic Proceedings|December 6, 2016
Opposition to Value-Based Cancer Care-Interests of Patients or Conflicts of Interest?Daniel A Goldstein
Environmental Health Perspectives|December 7, 2005
Pesticides and neurologic symptomsCarol Burns, Daniel A Goldstein
JAMA Oncology|September 8, 2018
Information Transparency in the Drug Approval Process-ReplyBishal Gyawali, Daniel A Goldstein
Pageof 14

Showing results (1-10 of 136) with videos related to

Sort By:
Pageof 14
JAMA Oncology|June 1, 2016
The Ethical and Practical Challenges of Value-Based Cancer Care at the Patient's BedsideDaniel A Goldstein
JAMA Oncology|October 7, 2017
Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient RegimenDaniel A Goldstein
Haematologica|May 2, 2018
Denosumab for bone lesions in multiple myeloma - what is its value?Daniel A Goldstein
Cancer|February 21, 2017
Financial toxicity in cancer care-Edging toward solutionsDaniel A Goldstein
Journal of Oncology Practice|May 5, 2016
Using Quality-Adjusted Life-Years in Cost-Effectiveness Analyses: Do Not Throw Out the Baby or the BathwaterDaniel A Goldstein
Cancer|May 11, 2016
Understanding the value of cancer drugs-the devil is in the detailDaniel A Goldstein
Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology|May 7, 2014
Tempest in a tea pot: How did the public conversation on genetically modified crops drift so far from the facts?Daniel A Goldstein
Mayo Clinic Proceedings|December 6, 2016
Opposition to Value-Based Cancer Care-Interests of Patients or Conflicts of Interest?Daniel A Goldstein
Environmental Health Perspectives|December 7, 2005
Pesticides and neurologic symptomsCarol Burns, Daniel A Goldstein
JAMA Oncology|September 8, 2018
Information Transparency in the Drug Approval Process-ReplyBishal Gyawali, Daniel A Goldstein
Pageof 14